Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of alisertib and navitoclax on gene expression in B16 melanoma tumors

ABSTRACT: To investigate how tumor cells respond to alisertib and navitoclax single agents and combonation therapy in vivo, mice with melanoma were treated with these agents or vehicle-contol. RNAseq was used to investigate gene expression in tumors

ORGANISM(S): Mus musculus

PROVIDER: GSE212127 | GEO | 2022/10/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effect of alisertib and navitoclax on gene expression in B16 melanoma tumors

Project description:Effect of alisertib and navitoclax on gene expression in B16 melanoma tumors

| PRJNA874062 | ENA

Salinomycin treatment of Alisertib induced senescent A549 cells

Project description:Bulk RNA-seq data of alisertib induced senescent cells treated with Salinomycin vs. Untreated

2024-11-25 | GSE279184 | GEO

RNA Sequencing MDA-MB-231 Treared with TGFβ and Alisertib

Project description:RNA sequencing was performed on MDA-MB-231 samples treated with TGFβ nad Alisertib to obtaine the TGFβ-mediated gene expression profile which is regulated by AURKA activity.

2020-12-31 | GSE160990 | GEO

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

Project description:This phase I trial studies the side effects and best dose of alisertib when given together with irinotecan hydrochloride in treating patients with advanced solid tumors or colorectal cancer. Irinotecan hydrochloride and alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

| 2150139 | ecrin-mdr-crc

Next Generation Sequencing was performed on MDSCs from tumors of control or alisertib treated tumor-bearing mice

Project description:The Aurora-A inhibitor alisertib shows encouraging activities in clinical trials against multiple malignances including advanced breast cancer. However, its mechanism of action remains unclear, especially regarding how the inflammatory microenvironment is involved in the efficacy of alisertib. Here, we demonstrated that Aurora-A inhibition directly reshapes the immune microenvironment through removal of tumor-promoting myeloid cells and enrichment of anti-cancer T lymphocytes, which restores a tumor-suppressive microenvironment and significantly contributes to the regression of murine mammary tumors. Mechanistically, the Aurora-A inhibitor effectively eliminated myeloid cells including myeloid-derived suppressor cells (MDSCs) and macrophages in tumors by triggering apoptosis of these cells. Further, Aurora-A inhibition could disrupt the immunosuppressive functions of MDSCs through inhibiting Stat3 mediated ROS production. These alterations led to significant increases in the proportion and the number of CD8+ and CD4+ T lymphocytes, which efficiently inhibited the proliferation of tumor cells. In summary, these data revealed that in addition to suppressing the proliferation of tumor cells, Aurora-A inhibitor directly modulates and restores an anti-tumor immune-microenvironment in breast cancer. Intriguingly, Aurora-A inactivation combined with PD-L1 blockade showed synergistic efficacy in the treatment of mammary tumors, providing an effective strategy for clinical trials of chemo-immunotherapy in breast cancer.

2021-10-21 | GSE121570 | GEO

Salinomycin treatment of Alisertib induced senescent A549 cells

Project description:Salinomycin treatment of Alisertib induced senescent A549 cells

| PRJNA1171320 | ENA

Cytokine Stimulation of ADAR-deleted B16 murine melanoma cells

Project description:ADAR was deleted from the B16 murine melanoma line using CRISPR/Cas9. The loss-of-function phenotype was assessed in vitro with cytokine stimulation or vehicle control.

2018-12-30 | GSE110708 | GEO

CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.

Project description:To determine whether blockade of the chemokine receptor CXCR4 might alter the tumor microenvironment and inhibit tumor growth, we tested the efficacy of the CXCR4 antagonist X4-136 as a single agent and in combination with various immune checkpoint inhibitors in the syngeneic murine melanoma model B16-OVA. We also tested its activity alone and in combination with axitinib in the renal cancer model Renca. We found that X4-136 exhibited potent single agent antitumor activity in the B16-OVA model that was additive to that of an anti-PDL1 antibody. The antitumor activities were associated with a reduction in the number of immunosuppressive regulatory T cells and myeloid-derived suppressor cells and an increase in the number of tumor-specific CD8/perforin cells in the tumor-microenvironment. Apart from these immune effects, X4-136 alone and in combination with checkpoint inhibitors inhibited the Akt/FOXO-3a cell survival pathway in vitro and in vivo, suggesting that it might have antitumor activity independent of its effects on immune cell trafficking. Similar effects on tumor growth and cytotoxic T lymphocytes infiltration were observed in the Renca model. These studies show that the effects of CXCR4 blockade on immune cell trafficking might serve as a useful adjunct to immune checkpoint inhibitors and other therapies in the treatment of cancer.

| S-EPMC6933081 | biostudies-literature

Single-cell RNA-seq of sorted CD8+ T cells from B16 melanoma tumors

Project description:CD8 T cells are the main effectors of the adaptive immune response against intracellular pathogens and cancer. Chronic antigen stimulation and inflammation lead to CD8 T cell differentiation and function that differ from those generated during acute infections. A comprehensive definition of the heterogeneity existing within both tumor-specific and total CD8 tumor-infiltrating T cells remains to be clearly established. To investigate this heterogeneity at the transcriptomic level, we performed paired single-cell RNA and TCR sequencing of >3500 CD8 T cells infiltrating B16 murine melanoma tumors, including cells of known tumor-specificity.

2019-10-10 | GSE116390 | GEO

RNA Sequencing MDA-MB-231 Treared with TGFβ and Alisertib

Project description:RNA Sequencing MDA-MB-231 Treared with TGFβ and Alisertib

| PRJNA675084 | ENA